Fifty 1 Labs (OTC: FITY) , through its subsidiary Fifty1 AI Labs, LLC, announced the successful completion of the REVIVE Adaptive Platform Trial (NCT ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 10 Best and Safe Dividend Stocks to Buy Now. Bristol-Myers Squibb Company (NYSE:BMY) presents a strong case for investors looking for both ...

For reference, Seeking Alpha's Quant system is driven by powerful computer processing and SA's special 'Quantamental' ...

(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Bristol Myers Squibb is taking a strategic leap, offloading five immunology assets, including three in clinical stages, to a ...

A police officer and one other person were shot at an office skyscraper in midtown Manhattan Monday evening, according to law ...

Bain Capital and Bristol Myers Squibb have formed a new biopharmaceutical company focused on developing new therapies for autoimmune diseases. The newly formed company launches with a $300 million ...